4 completed, 2 unknown, 1 active not recruiting, 1 enrolling by invitation. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 4, Unknown 2, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1 |
Follow Envarsus: new trials by email Literature Review of Envarsus trials Research Report on Envarsus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs Tacrolimus Pill, Tacrolimus capsule - Immunosuppression | Phase 4 | Active not recruiting | Edward Geissler | 322 | 2024-03-09 | 2026-11-05 |
| Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients Prograf, Envarsus - Liver Transplant Rejection, Immune System Suppression | Phase 4 | Enrolling by invitation | University Health Network, Toronto | 40 | 2024-01-01 | 2024-12-11 |
| Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations Tacrolimus, Immediate Release, Oral, Tacrolimus Extended Release Oral Tablet - Liver Transplantation, Immunosuppression | Phase 4 | Recruiting | University of British Columbia | 124 | 2023-01-09 | 2024-01-02 |
| Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy Mycophenolate Mofetil, Tacrolimus - Autoimmune Hepatitis | Phase 4 | Unknown | Leiden University Medical Center | 86 | 2022-01-19 | 2022-02-03 |
| Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients Tacrolimus Pill, Tacrolimus capsule - Prophylaxis Against Liver Transplant Rejection | Phase 4 | Completed | Edward Geissler | 268 | 2020-12-23 | 2026-11-05 |
| Envarsus Neurotoxicity Burden in Liver Transplant Patients Envarsus, Tacrolimus Immediate release - Neurotoxicity, Liver Transplant; Complications | Phase 4 | Completed | Medical University of South Carolina | 30 | 2020-01-31 | 2025-03-30 |
| Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus Tacrolimus - Transplant;Failure,Kidney | Phase 4 | Completed | Sentara Norfolk General Hospital | 46 | 2020-01-16 | 2024-02-29 |
| Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients Envarsus, IR Tacrolimus - Kidney Transplant; Complications, Toxicity | Phase 4 | Completed | University of California, Davis | 64 | 2018-04-01 | 2025-04-08 |
| AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation ENVARSUS, Standard twice daily tacrolimus - Kidney Transplant Failure and Rejection | Phase 4 | Unknown | University Hospital Birmingham NHS Foundation Trust | 40 | 2017-04-01 | 2016-12-29 |
Neurotoxicity Syndromes (3) · Drug-Related Side Effects and Adverse Reactions (1) · Hepatitis, Autoimmune (1) · Rejection, Psychology (1) · Tremor (1)
Edward Geissler (2) · Leiden University Medical Center (1) · Medical University of South Carolina (1) · Sentara Norfolk General Hospital (1) · University Health Network, Toronto (1) · University Hospital Birmingham NHS Foundation Trust (1) · University of British Columbia (1) · University of California, Davis (1)
United States (3) · Canada (2) · Germany (2) · Netherlands (1)
Adnan Sharif, MD (1) · Bart van Hoek (1) · Bernhard Banas, MD (1) · Derek Dubay, MD (1) · Hans J. Schlitt, MD (1) · Jo-Ann Ford, RN (1) · Ling-Xin Chen, MD (1) · Nazia Selzner, MD (1) · Thomas McCune, MD (1) · Trana Hussaini, Pharm D (1)
PMID 37170284, PMID 38233878, PMID 41089174
2023 (1)